The Role of Host Gender in the Pathogenesis of Cryptococcus neoformans Infections

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  McClelland, Erin E ^a,e   Hobbs, Letizia M ^a,f   Rivera, Johanna ^b   Casadevall, Arturo ^b   Potts, Wayne K ^c   Smith, Jennifer M ^a   Ory, Jeramia J ^a,d  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d KING'S COLLEGE   (United States)

^e MIDDLE TENNESSEE STATE UNIVERSITY   (United States)

^f Musculoskeletal Transplant Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GLUCORONOXYLOMANNAN; MANNAN; TESTOSTERONE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; GENDER; HOST; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LUNG HOMOGENATE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; SURVIVAL;

ANIMALS; CD4 LYMPHOCYTE COUNT; CELL DEATH; CELLS, CULTURED; COINFECTION; CRYPTOCOCCUS NEOFORMANS; ESTRADIOL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MACROPHAGES; MALE; MENINGITIS, CRYPTOCOCCAL; MICE, INBRED BALB C; PHAGOCYTOSIS; POLYSACCHARIDES; SEX FACTORS; SURVIVAL ANALYSIS; TESTOSTERONE;

FILOBASIDIELLA NEOFORMANS;

EID: 84878542973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063632     Document Type: Article

References (47)

1. Alanio A, Desnos-Ollivier M, Dromer F, (2011) Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. MBio 2(4): e00158-11.
2. Mansour MK, Vyas JM, Levitz SM, (2011) Dynamic virulence: real-time assessment of intracellular pathogenesis links Cryptococcus neoformans phenotype with clinical outcome. MBio 2(5): e00217-11.
3. Rapp RP (2004) Changing strategies for the management of invasive fungal infections. Pharmacotherapy 24: 4S-28S; quiz 29S-32S.
4. Edwards VE, Sutherland JM, Tyrer JH, (1970) Cryptococcosis of the central nervous system. Epidemiological, clinical, and therapeutic features. J Neurol Neurosurg Psychiatry 33: 415-425.
5. Hajjeh RA, Brandt ME, Pinner RW, (1995) Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 17: 303-320.
6. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, et al. (1995) Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 20: 611-616.
7. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, et al. (1999) Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 179: 449-454.
8. Lamagni TL, Evans BG, Shigematsu M, Johnson EM, (2001) Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 126: 397-414.
9. Mohr JA, Long H, McKown BA, Muchmore HG, (1972) In vitro susceptibility of Cryptococcus neoformans to steroids. Sabouraudia 10: 171-172.
10. Davis J, Zheng WY, Glatman-Freedman A, Ng JA, Pagcatipunan MR, et al. (2007) Serologic evidence for regional differences in pediatric cryptococcal infection. Pediatr Infect Dis J 26: 549-551.
11. Mohr JA, Tacker RJ, Devlin RF, Felton FG, Rhoades ER, et al. (1969) Estrogen-Stimulated Phagocytic Activity in Human Cryptococcosis. Am Rev Respir Dis 99: 979.
12. Mohr JA, Muchmore HG, Tacker R, (1974) Stimulation of phagocytosis of Cryptococcus neoformans in human cryptococcal meningitis. J Reticuloendothel Soc 15: 149-154.
13. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4: e21.
14. Bisson GP, Nthobatsong R, Thakur R, Lesetedi G, Vinekar K, et al. (2008) The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 49: 227-229.
15. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, et al. (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47: 561-570.
16. Granger DL, Perfect JR, Durack DT, (1985) Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest 76: 508-516.
17. Casadevall A, Mukherjee J, Scharff MD, (1992) Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods 154: 27-35.
18. Taborda CP, Casadevall A, (2001) Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol 166: 2100-2107.
19. Perfect JR, Lang SD, Durack DT, (1980) Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 101: 177-194.
20. Norden AD, Drappatz J, Wen PY, Claus EB, (2011) Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 101: 487-493.
21. Maman D, Pujades-Rodriguez M, Subtil F, Pinoges L, McGuire M, et al. (2012) Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa. PLoS One 7: e31078.
22. Zachariah R, Harries K, Moses M, Manzi M, Line A, et al. (2009) Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health 14: 713-721.
23. Mzileni MO, Longo-Mbenza B, Chephe TJ, (2008) Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital. Pol Arch Med Wewn 118: 548-554.
24. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, et al. (2009) Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 21: 70-77.
25. Melo LS, Lacerda HR, Campelo E, Moraes E, Ximenes RA, (2008) Survival of AIDS patients and characteristics of those who died over eight years of highly active antiretroviral therapy, at a referral center in northeast Brazil. Braz J Infect Dis 12: 269-277.
26. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, et al. (2008) Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 168: 532-540.
27. Zwang J, Garenne M, Kahn K, Collinson M, Tollman SM, (2007) Trends in mortality from pulmonary tuberculosis and HIV/AIDS co-infection in rural South Africa (Agincourt). Trans R Soc Trop Med Hyg 101: 893-898.
28. Oliveira HB, Marin-Leon L, Cardoso JC, (2004) [Differences in mortality profile of tuberculosis patients related to tuberculosis-AIDS co-morbidity]. Rev Saude Publica 38: 503-510.
29. Biber CL, Jaker MA, Kloser P, Auerbach SB, Rhoads GG, (1999) A study of sex differences in presentation for care of HIV. AIDS Patient Care STDS 13: 103-110.
30. Zaragoza O, Casadevall A, (2004) Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6: 10-15.
31. Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, et al. (2007) Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell 6: 48-59.
32. Bulmer GS, Sans MD, (1968) Cryptococcus neoformans. 3. Inhibition of phagocytosis. J Bacteriol 95: 5-8.
33. Kozel TR, Mastroianni RP, (1976) Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect Immun 14: 62-67.
34. Monari C, Bistoni F, Casadevall A, Pericolini E, Pietrella D, et al. (2005) Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J Infect Dis 191: 127-137.
35. Retini C, Vecchiarelli A, Monari C, Bistoni F, Kozel TR, (1998) Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun 66: 664-669.
36. Chiapello LS, Baronetti JL, Aoki MP, Gea S, Rubinstein H, et al. (2004) Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan. Immunology 113: 392-400.
37. Delfino D, Cianci L, Lupis E, Celeste A, Petrelli ML, et al. (1997) Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components. Infect Immun 65: 2454-2456.
38. Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, et al. (1996) Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun 64: 2897-2903.
39. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, et al. (1996) Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 64: 2846-2849.
40. McClelland EE, Casadevall A, Eisenman HC (2007) Pathogenesis of Cryptococcus neoformans. In: Kavanagh K, editor. New Insights in Medical Mycology. Dordrecht, The Netherlands: Springer. 131-157.
41. Yamaguchi M, Ohkusu M, Biswas SK, Kawamoto S, (2007) Cytological study of cell cycle of the pathogenic yeast Cryptococcus neoformans. Nihon Ishinkin Gakkai Zasshi 48: 147-152.
42. McQuiston T, Luberto C, Del Poeta M, (2011) Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophages. Microbiology 157: 1416-1427.
43. Heitman J, Kozel TR, Kwon-Chung J, Perfect JR, Casadevall A (2011) Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press.
44. Alvarez M, Burn T, Luo Y, Pirofski LA, Casadevall A, (2009) The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol 9: 51.
45. Lortholary O, Improvisi L, Fitting C, Cavaillon JM, Dromer F, (2002) Influence of gender and age on course of infection and cytokine responses in mice with disseminated Cryptococcus neoformans infection. Clin Microbiol Infect 8: 31-37.
46. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
47. Klein SL, (2004) Hormonal and immunological mechanisms mediating sex differences in parasite infection. Parasite Immunol 26: 247-264.